Fig. 4

Full-length OPG-Fc treatment increased SERCA activity and SERCA-2a protein levels in fast-twitch dystrophic EDL muscles. a Full-length OPG-Fc [1 mg/kg/d] treatment, but not muscle RANK deletion, increased SERCA activity over different Ca²⁺ concentrations ranging from pCa 7,0–4,5 in homogenized dystrophic EDL muscles (b) with no change in pCa50 value. c Full-length OPG-Fc treatment rescued maximal ATPase activity (Vmax) in dystrophic EDL muscles. d Consistent with an increase in SERCA activity, full-length OPG-Fc markedly enhanced 6-fold SERCA-2a protein levels but not SERCA-1a, compared to PBS-treated mdx mice. Data are shown as mean values +/− s.e.m.; one way ANOVA and Tukey’s post-hoc tests; significantly different from PBS-treated mdx mouse; * p < 0.05, ** p < 0.01